Trimeris to begin Phase III trials

TRMS and partner F. Hoffmann-La Roche (SWX:ROCZ) will begin in the next several weeks two Phase III studies of its T-20 gp41 peptide analog viral fusion inhibitor to treat HIV infection/AIDS. The stud...